Summary: During this panel discussion, executives share how their companies adapted to the challenges and what lessons they will take forward to ensure...

Summary: In December 2021, John Chiminski was featured on the expert panel of STAT’s "A Look Ahead at Biotech in 2022" event, which focused on the ongoing battle against the SARS-CoV-2 virus and explored what might be in store for the biotech industry in the years to come.

Summary: On December 13, 2021, EuropaBio hosted the final event of its 25th Anniversary programme with a focus on the story of mRNA.

Catalent’s CEO John Chiminski & Endpoints News’ John Carroll discuss their predictions for what 2022 has in store for the biopharma industry.

Summary: Supply chains have come under intense pressure, and companies have had to adapt to this “new normal” to avoid delays. During this Q&A, Catalent discusses....

Summary: During this webinar, we reviewed progress in several areas of advanced development and their impact on readiness for large scale manufacturing.

Summary: Join us as we honor a group of 20 extraordinary women who are making lasting impacts in the drug development field.

Summary: Join Claudia Berdugo, Ph.D., Director of Process Development at Catalent Biologics, for a podcast where she discusses N-1 perfusion and how Catalent Biologics works toward process improvements....

Summary: In this informative interview with Phacilitate, Boris Greber and Thomas Marx answer questions about the position of induced pluripotent stem cells in today’s advanced therapies market and the transformative power latent in their clinical application.

Summary: In this ebook, we bring you expert insights into the advantages that various cellular starting materials have, with a particular focus on human induced pluripotent stem cells (iPSCs).